FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011090250> ?p ?o ?g. }

• W3011090250 endingPage "239" @default.
• W3011090250 startingPage "229" @default.
• W3011090250 abstract "To evaluate the cost-effectiveness of risankizumab versus other biologic treatments (adalimumab, infliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, and guselkumab) of moderate-to-severe psoriasis in Japan.A Markov cohort-level model was constructed to estimate quality-adjusted life years (QALYs) and costs for each treatment over a lifetime horizon. The model simulated patients' transition through one line of active biologic therapy followed by best supportive care and death. Transition probabilities were informed by network meta-analyses of Psoriasis Activity and Severity Index responses and adverse event-related discontinuation in clinical trials, as well as published real-world evidence and national mortality rates. Costs were evaluated from the health system, societal, and patient out-of-pocket perspectives.Risankizumab was expected to provide 0.30-0.89 additional QALYs versus comparator biologics. Under the health system perspective, incremental cost-effectiveness ratios (ICERs) of risankizumab ranged from ¥2,545,812/QALY versus ustekinumab to ¥6,077,134/QALY versus adalimumab. Societal ICERs were lower, ranging from ¥921,770/QALY to ¥4,350,879/QALY. From the patient perspective, risankizumab was estimated to be cost-saving versus four comparators and was associated with ICERs of <¥500,000/QALY versus the remaining comparators.Risankizumab was associated with higher QALYs and, based on typical willingness-to-pay benchmarks (¥5-6.7 million/QALY), considered cost-effective versus other biologics for the treatment of psoriasis in Japan." @default.
• W3011090250 created "2020-03-23" @default.
• W3011090250 creator A5021139854 @default.
• W3011090250 creator A5021805688 @default.
• W3011090250 creator A5024531277 @default.
• W3011090250 creator A5056774902 @default.
• W3011090250 creator A5068637941 @default.
• W3011090250 creator A5090350403 @default.
• W3011090250 date "2020-04-17" @default.
• W3011090250 modified "2023-10-16" @default.
• W3011090250 title "An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan" @default.
• W3011090250 cites W1692288477 @default.
• W3011090250 cites W1959946112 @default.
• W3011090250 cites W1973201198 @default.
• W3011090250 cites W1973354423 @default.
• W3011090250 cites W1988914585 @default.
• W3011090250 cites W2003687140 @default.
• W3011090250 cites W2013719325 @default.
• W3011090250 cites W2027145044 @default.
• W3011090250 cites W2046549669 @default.
• W3011090250 cites W2064709295 @default.
• W3011090250 cites W2073113169 @default.
• W3011090250 cites W2080090843 @default.
• W3011090250 cites W2080165152 @default.
• W3011090250 cites W2109525818 @default.
• W3011090250 cites W2113369166 @default.
• W3011090250 cites W2119440126 @default.
• W3011090250 cites W2166811019 @default.
• W3011090250 cites W2326643498 @default.
• W3011090250 cites W2418506270 @default.
• W3011090250 cites W2490073661 @default.
• W3011090250 cites W2557867537 @default.
• W3011090250 cites W2567289819 @default.
• W3011090250 cites W2570141807 @default.
• W3011090250 cites W2605636712 @default.
• W3011090250 cites W2776511988 @default.
• W3011090250 cites W2788385232 @default.
• W3011090250 cites W2810907322 @default.
• W3011090250 cites W2887412253 @default.
• W3011090250 cites W2930461440 @default.
• W3011090250 cites W2936261791 @default.
• W3011090250 cites W2955205003 @default.
• W3011090250 cites W2955490990 @default.
• W3011090250 cites W3000072935 @default.
• W3011090250 cites W3005392748 @default.
• W3011090250 doi "https://doi.org/10.1080/09546634.2020.1744505" @default.
• W3011090250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32178555" @default.
• W3011090250 hasPublicationYear "2020" @default.
• W3011090250 type Work @default.
• W3011090250 sameAs 3011090250 @default.
• W3011090250 citedByCount "3" @default.
• W3011090250 countsByYear W30110902502020 @default.
• W3011090250 countsByYear W30110902502021 @default.
• W3011090250 crossrefType "journal-article" @default.
• W3011090250 hasAuthorship W3011090250A5021139854 @default.
• W3011090250 hasAuthorship W3011090250A5021805688 @default.
• W3011090250 hasAuthorship W3011090250A5024531277 @default.
• W3011090250 hasAuthorship W3011090250A5056774902 @default.
• W3011090250 hasAuthorship W3011090250A5068637941 @default.
• W3011090250 hasAuthorship W3011090250A5090350403 @default.
• W3011090250 hasBestOaLocation W30110902501 @default.
• W3011090250 hasConcept C112930515 @default.
• W3011090250 hasConcept C126322002 @default.
• W3011090250 hasConcept C16005928 @default.
• W3011090250 hasConcept C187212893 @default.
• W3011090250 hasConcept C2776260265 @default.
• W3011090250 hasConcept C2778715236 @default.
• W3011090250 hasConcept C2778975655 @default.
• W3011090250 hasConcept C2779134260 @default.
• W3011090250 hasConcept C2779745271 @default.
• W3011090250 hasConcept C2779786854 @default.
• W3011090250 hasConcept C2780132546 @default.
• W3011090250 hasConcept C2780564577 @default.
• W3011090250 hasConcept C3019080777 @default.
• W3011090250 hasConcept C64332521 @default.
• W3011090250 hasConcept C71924100 @default.
• W3011090250 hasConceptScore W3011090250C112930515 @default.
• W3011090250 hasConceptScore W3011090250C126322002 @default.
• W3011090250 hasConceptScore W3011090250C16005928 @default.
• W3011090250 hasConceptScore W3011090250C187212893 @default.
• W3011090250 hasConceptScore W3011090250C2776260265 @default.
• W3011090250 hasConceptScore W3011090250C2778715236 @default.
• W3011090250 hasConceptScore W3011090250C2778975655 @default.
• W3011090250 hasConceptScore W3011090250C2779134260 @default.
• W3011090250 hasConceptScore W3011090250C2779745271 @default.
• W3011090250 hasConceptScore W3011090250C2779786854 @default.
• W3011090250 hasConceptScore W3011090250C2780132546 @default.
• W3011090250 hasConceptScore W3011090250C2780564577 @default.
• W3011090250 hasConceptScore W3011090250C3019080777 @default.
• W3011090250 hasConceptScore W3011090250C64332521 @default.
• W3011090250 hasConceptScore W3011090250C71924100 @default.
• W3011090250 hasFunder F4320309117 @default.
• W3011090250 hasIssue "1" @default.
• W3011090250 hasLocation W30110902501 @default.
• W3011090250 hasLocation W30110902502 @default.
• W3011090250 hasLocation W30110902503 @default.
• W3011090250 hasOpenAccess W3011090250 @default.
• W3011090250 hasPrimaryLocation W30110902501 @default.

• next